Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.

Cardiovasc Diabetol · 2023 · PMC9999503 · PMID 36899387

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

After adjustment, SGLT2i users exhibited significant reductions in risk of HHF: HR 0.65 (95% CI 0.61, 0.69) and RD − 23.0 (95% CI − 14.5, − 31.4), and numerical decreases in MI or stroke that did not reach statistical significance: HR 0.90 (95% CI 0.79, 1.02) and RD − 1.0 (95% CI − 3.0, 1.1).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.